Courses

This course describes how bowel cancer comes about, and explains the reasons why some patients might be given treatments such as EGFR-targeted antibodies (cetuximab and panitumumab), angiogenesis inhibitors (bevacizumab and regorafenib), or immune checkpoint inhibitors (pembrolizumab) as part of their treatment.

This course provides an overview of the targeted therapies and immunotherapies given to some people with oesophageal, stomach, pancreatic or liver cancer, or cancers of the biliary system

This course explains why breast cancer arises, the different ways that the DNA in our cells gets damaged and the targeted treatments that match a few of the known mutations. It also explores the science behind hormone therapies, targeted therapies, and immunotherapies given to patients with hormone receptor-positive, HER2-positive, and triple-negative breast cancer.

During this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.